4//SEC Filing
DiRaimondo Thomas 4
Accession 0001415889-24-024076
CIK 0001817713other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 7:31 PM ET
Size
7.3 KB
Accession
0001415889-24-024076
Insider Transaction Report
Form 4
DiRaimondo Thomas
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-09-27$47.22/sh−675$31,877→ 97,938 total - Sale
Common Stock
2024-09-27$46.21/sh−4,325$199,840→ 98,613 total
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- [F2]The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024.
- [F4]The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0002005618
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 7:31 PM ET
- Size
- 7.3 KB